AngioDynamics Inc Q4 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : First off, just the Auryon product, the uses seem to be expanding as you talk about the thrombectomy and then going into coronary. Just trying to kind of get wrapped my head around, one, as we look at the business today that was really solid growth, how much of that was U.S. versus OUS driven? How much of that is outpatient versus OBL? And then just 2, how should we think about this strategically as you move forward? It seems like this product is becoming a bigger and bigger piece of the company's overall Med Tech franchise and finding more uses.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : And then given the -- moving into these new indications, are there major studies that we should be tracking? How do we think about that? And then just on the AlphaVac, that seems obviously to be going a little slower than original expectations. And how -- is that until we get the F18 for PE, you're going to be kind of hands tied behind your back on that one in terms of growth? How should we think about that until the PE indication comes? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 12, 2023 / 12:00PM, ANGO.OQ - Q4 2023 AngioDynamics Inc Earnings Call

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : And last question, I promise, just on PRESERVE study's enroll. Just give us timelines for data, submission, approval. I assume this is a 510(k) I believe. How should we think about that? And then how do you expect the impact on the business? How should we think about the timing for that to -- the data be disseminated into the marketplace and potentially drive that business?